Drug Trial Radar · NCT02707861
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Mar 2016
Primary completion
Nov 2018
Study completion Nov 2018
Sponsor
- Lead sponsor
- TaiMed Biologics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Westat
- First posted
- Mar 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited treatment options. This study will collect further information on the safety and tolerability of intravenously administered (IV) ibalizumab combined with an optimized background regimen for treating multi-drug resistant HIV-1 infection, and will provide continuing access to ibalizumab for patients completing a prior ibalizumab clinical trial.
Conditions
- HIV
Interventions
ibalizumabDrug
Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
Optimized Background RegimenDrug
An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of Ibalizumab + OBRTime frame: Through 48 weeks
- Discontinuations Due to Adverse Events Related to IbalizumabTime frame: 48 weeks
- Effectiveness of Ibalizumab + OBR (Cohort 2 Only)Time frame: 7 days
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
Long Beach Education and Research Consultants
Long Beach, California
Southern California Permanente Medical Group
Los Angeles, California
Ruane Clinical Research Institute Inc.
Los Angeles, California
Charles R. Drew University of Medicine and Science, Clinical and Translational Research Center
Los Angeles, California
Anthony Mills MD Inc.
Los Angeles, California
Palmtree Clinical Research, Inc.
Palm Springs, California
eStudy Site
San Francisco, California
Kaiser Foundation Research Institute
San Francisco, California
Yale University
New Haven, Connecticut
Georgetown University School of Medicine
Washington D.C., District of Columbia
Gary Richmond, MD, PA
Fort Lauderdale, Florida
AIDS Healthcare Foundation - Kinder Medical Group
Miami, Florida
AIDS Healthcare Foundation - South Beach
Miami, Florida
Orlando Immunology Center
Orlando, Florida
Triple O Research Institute
West Palm Beach, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
University of Hawaii - John A. Burns School of Medicine
Honolulu, Hawaii
Howard Brown Health Center
Chicago, Illinois
National Institute of Allergy & Infectious Diseases
Bethesda, Maryland
ID Research Institute
Springfield, Massachusetts
Central West Clinical Research
St Louis, Missouri
AIDS Healthcare Foundation - Manhattan Midtown HCC
New York, New York
Chelsea Village Medical
New York, New York
Jacobi Medical Center
The Bronx, New York
East Carolina University
Greenville, North Carolina
Philadelphia FIGHT
Philadelphia, Pennsylvania
St. Jude's Children's Research Hospital
Memphis, Tennessee
St. Hope Foundation Community Health Center
Bellaire, Texas
North Texas Infectious Disease Consultants
Dallas, Texas
Crofoot Research Center
Houston, Texas
Research Access Network
Houston, Texas
Clinical Research PR, Inc.
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.